Akamis Bio

Akamis Bio is a clinical-stage oncology company building intravenously delivered, tumor-targeted gene therapies on its Tumor-Specific Immuno-Gene (T-SIGn) platform. Using a replication-competent, directed-evolution-engineered group B adenovirus that selectively infects epithelial-derived solid tumors, Akamis turns cancer cells into local 'drug factories' that express immune-modulating payloads inside the tumor while sparing healthy tissue. Headquartered in Cambridge, Massachusetts (with UK roots as the former PsiOxus Therapeutics), its lead program NG-350A delivers a CD40 agonist antibody directly to primary and metastatic tumors.